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Sir,
The paper by Renaud et al (2015) begins and ends with acknowledgements
that there has been no proof of effectiveness of pulmonary metastasectomy in
colorectal cancer. The authors are correct. No difference in survival
attributable to surgical removal of lung metastases has been shown in a
controlled trial and yet it is regarded by them as ‘steadily gaining acceptance’.
Given the heterogeneity of patients with colorectal cancer, the variability in
biology, the variety of treatments involved, and the variable time course
between metastasectomy and death, a simple mechanistic cause and effect
relationship cannot be derived from observational follow-up data (Glasziou
et al, 2007; Fiorentino and Treasure, 2013a,b). Because of the lack of evidence
for effectiveness the PulMiCC trial (Pulmonary Metastasectomy in Colorectal
Cancer) seeks to answer that question (http://public.ukcrn.org.uk/search/
StudyDetail.aspx?StudyID=9018).
The differences in survival according to whether the patients had V-Ki-ras2
Kirsten rat sarcoma viral oncogene homologue (KRAS) or V-raf Murine
sarcoma viral oncogene homologue B1 (BRAF) are striking as displayed in a
Kaplan–Meier plot (Po0.0001). Survival of patients with KRAS is worse than
those with wild type and for the 19 patients with BRAF is lower still. On the
basis of these data it would seem to be foolhardy to offer metastasectomy to
BRAF positive patients. That much seems clear. The study shows the influence
of oncogenes on survival but these are likely to be general prognostic
factors, not predictors of the effectiveness of lung metastasectomy itself
(Simms et al, 2013).
These are highly selected patients collected over 14 years, barely more than
one per month. They were selected because of their very limited disease: ‘All of
the patients were considered completely cured of their primary tumour at the
time of thoracic metastasectomy, and all pulmonary metastases were
metachronous’ (Renaud et al, 2015). They were asymptomatic, fit for surgery
and individually picked for operation after careful assessment including a
judgement of their ‘survivability’ (Treasure et al, 2015) at the time of selection.
They are out in the longer lived tail of the survival curve for patients with
metastatic colon cancer (Utley et al, 2008) and a survival effect attributable to
metastasectomy cannot be estimated from these data.
The statistical interpretation lacks critical insight. The authors performed
an analysis for the well know factors predictive of early death after
metastasectomy: more than one metastasis, any elevation of CEA, an interval
shorter than 3 years since primary resection and involvement of mediastinal
lymph nodes (Gonzalez et al, 2013). The failure of CEA and short intervals to
show in this analysis is a simple example of a beta error. Adverse prognostic
features have been systematically excluded by clinical selection so variation in
prognosis attributable to them cannot be excluded (Utley and Treasure, 2008).
The choice of citations is also misleading. The publications cited for
metastasectomy are follow-up studies (Treasure and Utley, 2007) from 1984 to
1996, reporting surgical series that closed 420 years ago. None of four
systematic reviews were cited (Pfannschmidt et al, 2007; Fiorentino et al, 2010;
Pfannschmidt et al, 2010; Gonzalez et al, 2013). It is well known that ‘citation
distortions create unfounded authority’ (Greenberg, 2009). The problem has
been well exemplified in lung metastasectomy for colorectal cancer
(Fiorentino et al, 2011).
The authors conclude by saying: ‘Lung metastasectomy of CRC is steadily
gaining acceptance in the field of thoracic surgery, although it remains a
subject of debate because of the absence of recent comparisons between simple
follow-up and surgery’. There have been no randomised trials of metasta-
sectomy in any tumour type and its effect on survival is therefore conjectural.
But recently reported RCTs of the effect of intensive follow-up, with the
intention of improving survival by operating on recurrent disease, show no
survival benefit (Primrose et al, 2014; Treasure et al, 2014). This is indirect
evidence casting further doubt on effectiveness of metastasectomy in
colorectal cancer. It is hoped that the Cancer Research UK funded PulMiCC
trial will bring some evidence to this important question.
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